BackProtagonist Therapeutics Overview

Protagonist Therapeutics Net Tangible Assets

Protagonist Therapeutics's net tangible assets is $840M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$841.54M
25.98% YoYΔ $173.53M vs prior year quarter

Peer average / median

Loading

Protagonist Therapeutics Net Tangible Assets History

Loading

Protagonist Therapeutics vs. peers: Net Tangible Assets Comparison

Loading

Protagonist Therapeutics Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Protagonist Therapeutics (PTGX) FAQ

Protagonist Therapeutics (PTGX) currently reports a net tangible assets of $840M as of June 2026. That compares with $670M in the prior-year period — up 26.0% year over year. Use the charts on this page to explore Protagonist Therapeutics's net tangible assets history and peer comparisons.

Protagonist Therapeutics's net tangible assets increased from $670M to $840M — a 26.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Protagonist Therapeutics reported $840M in net tangible assets as of June 2026. That compares with $670M in the prior-year period — up 26.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $840M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Protagonist Therapeutics, and consider following PTGX for alerts when major investors trade the stock.

Protagonist Therapeutics is classified in the Healthcare sector. On net tangible assets, it currently shows $840M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PTGX with unrelated industries.